Roche drops after immunotherapy drug for cancer disappoints

  • 📰 BDliveSA
  • ⏱ Reading Time:
  • 32 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 16%
  • Publisher: 63%

Law Law Headlines News

Second trial results show combined treatment did not slow spread of lung cancer

Development of a new cancer treatment pioneered by Roche was thrown into doubt on Wednesday when the immunotherapy drug failed to slow progression of lung cancer in a second trial, hitting the Swiss pharmaceutical maker’s share price.

The Roche share price fell as much as 7.4% to their lowest in almost a year. The share was trading down 6.3% before midday, dragging the Stoxx Europe 600 Health Care index 1.2% lower. “While these results are not what we hoped for in our first analysis, we look forward to seeing mature overall survival for this study to determine next steps,” said Roche chief medical officer Levi Garraway.

Tigit is a receptor found on immune system cells as a backstop to prevent misguided immune attacks against normal body tissue. Some cancer types, however, exploit Tigit to grow unnoticed by cell-killing immune cells.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

I was scammed through Bitcoin couple of months ago, I started hating Bitcoin until I was introduced to Allison_Grillo, and I gave Bitcoin trading another try, I successfully withdrew $35,000 after two weeks of trading, am so grateful Allison_Grillo thank you.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 12. in LAW

Law Law Latest News, Law Law Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Blow to Roche's cancer immunotherapy prospects as second trial failsDevelopment of a new cancer immunotherapy pioneered by Roche was thrown in doubt on Wednesday when its drug tiragolumab failed to slow the progression of lung cancer in a second trial. I'm really grateful for all the efforts you have render to me with my little investment of $7000 and with joy over me after withdrawing $70,000 with your help Williamchurch07 thank you for everything you have done for me and my family Williamchurch07 There’s HOPE ❤️‍🩹
Source: SundayTimesZA - 🏆 47. / 51 Read more »

Blow to Roche's cancer immunotherapy prospects as second trial failsDevelopment of a new cancer immunotherapy pioneered by Roche was thrown in doubt on Wednesday when its drug tiragolumab failed to slow the progression of lung cancer in a second trial. I'm really grateful for all the efforts you have render to me with my little investment of $7000 and with joy over me after withdrawing $70,000 with your help Williamchurch07 thank you for everything you have done for me and my family Williamchurch07 There’s HOPE ❤️‍🩹
Source: SundayTimesZA - 🏆 47. / 51 Read more »